الفهرس 
Introduction and Aim of the work
EpidemiologyOnly 14 pages are availabe for public view
 |  | from | 201 |  |  |
| | | from | 201 | | |
Abstract
Malignant lymphomas are the most common hematological malignancy in the world. Epidemiologic studies have shown remarkable differences in the distribution of lymphoma subtypes between Asia and western populations.
The goal of this study is to analyse the results of treatment of lymphoma patients at clinical oncology department at Assuit university hospital in period between January 2007 to December 2011 and also study the characteristics of the patients, clinicopathological features of lymphoma, overall survival, disease free survival and the relation of prognostic factors and survival .
This study included 96 cases of lymphoma received treatment at clinical oncology department with identification of patients disease characteristics (age, sex, pathology, presentation, stage, first line treatment and response to it, second line treatment and response to it, relapse ) overall survival, disease free survival, prognostic factors for survival were also recorded. It was found that:-
Age ranges between 17-85 years old with average of 41 years old for patients with Hodgkin lymphoma, and between 3-80 years old with average of 47 years for patients with Non Hodgkin lymphoma patients.
Incidence of Hodgkin lymphoma in female 52.8% while in male 47.2%. *Incidence of Non Hodgkin lymphoma in female 49.4 % while in male 50.6%.
Hodgkin lymphoma patients represent 31.9% among total number of lymphoma while Non Hodgkin lymphoma patients represent 68.1% .
All Hodgkin lymphoma cases are of classic type with 47.2% of them are of nodular sclerosing subtype .
Intermediate grade Non Hodgkin lymphoma represents the highest incidence with percentage 45.5 % among all Non Hodgkin patients .
All Hodgkin lymphoma cases have nodal presentation while only 68.8% of Non Hodgkin lymphoma patients have nodal presentation and 31.2 %with extranodal presentation including stomach ,bone and pleura.
Most Hodgkin lymphoma cases (47.1%) are with stage III and also most Non Hodgkin patients (38.7%) .
B symptoms are present in small number of Hodgkin and Non Hodgkin lymphoma cases (29.4 and 30.6% respectively ).
Hodgkin lymphoma patients were treated with ABVD regimen (97.1%) while small number were treated with Stanford V (2.9%) as a first line treatment with number of cycles ranging from 2-8 cycles .
Non Hodgkin patients were treated with CHOP regimen (91.9%) and small number were treated with CVP (8.1%) as a first line treatment with number of cycles ranging from 2-8 cycles .
Total response of Hodgkin lymphoma patients to first line treatment was 41.2 % and of Non Hodgkin patients was 56.5% .
Other chemotherapy regimens were used (BEACOPP-COPP-DHAP-ICE-MINE) as second line treatment in case of recurrence of Hodgkin and Non Hodgkin lymphoma .
Recurrence was observed in 5.9% in Hodgkin lymphoma cases and 14.5% in Non Hodgkin lymphoma cases .
Median survival was 48 months in Hodgkin lymphoma cases 36 months in Non Hodgkin lymphoma cases and 5- year overall survival 73.52% for Hodgkin lymphoma cases and 69.35% for Non Hodgkin lymphoma cases.
Disease free survival was 12 months on average for Hodgkin lymphoma and Non Hodgkin lymphoma patients and 2 -year disease free survival was 38.2% , 27.7% respectively. The most important prognostic factors proved to increase overall survival of patients were the stage of the disease and the complete response to the first line treatment.